APLS Apellis Pharmaceuticals, Inc.
Healthcare$41.03+0.00%ClosedMarket Cap: $5.25B
As of 2026-05-25
Valuation
P/E (TTM)
232.90
PEG
2.09
P/B
12.46
P/S
4.75
EV/EBITDA
30.04
DCF Value
$-1,698.11
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.1%
Operating Margin
14.9%
Net Margin
12.1%
ROE
39.7%
ROA
12.3%
ROIC
18.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $268.3M | 84.8% | $26.5M | $18.7M | $— | — |
| Q4 null | $199.9M | 85.1% | $-51.1M | $-59.0M | $— | — |
| FY null | $1.00B | 89.8% | $55.4M | $22.4M | $— | — |
| Q3 null | $458.6M | 94.7% | $223.2M | $215.7M | $— | — |
| Q2 null | $178.5M | 92.1% | $-33.3M | $-42.2M | $— | — |
| Q1 null | $166.8M | 79.4% | $-83.3M | $-92.2M | $— | — |
| Q4 null | $212.5M | 80.8% | $-26.2M | $-36.4M | $— | — |
| FY null | $781.4M | 84.9% | $-165.0M | $-197.9M | $— | — |
| Q3 null | $196.8M | 83.0% | $-47.3M | $-57.4M | $— | — |
| Q2 null | $199.7M | 88.2% | $-29.4M | $-37.7M | $— | — |
| Q1 null | $172.3M | 88.0% | $-62.1M | $-66.4M | $— | — |
| Q4 2023 | $146.4M | 86.4% | $-84.5M | $-88.6M | $-0.73 | — |